• RXC008 Receives US FDA Fast Track Designation

    Read more
  • US FDA lifts Partial Clinical Hold on Zelasudil

    Read more
  • Redx presents encouraging signal searching data for zelasudil (RXC007) as a well-tolerated treatment for Idiopathic Pulmonary Fibrosis at ERS

    Read more
  • Redx Pharma to present new Phase 2a data for zelasudil (RXC007) at ERS

    Read more
  • Redx presents Phase 1 data supporting RXC008 at DDW 2025

    Read more
  • Redx Pharma Concludes Trading on JP Jenkins

    Read more
  • Redx Scientist Awarded the 2025 Malcolm J. Campbell Memorial Prize

    Read more
  • Redx Presents Phase 1 Data on RXC008 at ECCO Conference

    Read more
  • Redx Presents Preclinical Data on RXC008 at the UEG Week

    Read more
  • Redx Reports Encouraging Zamaporvint Phase 2 Data

    Read more